Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Poe Hirr Hsyu"'
Autor:
Wells A. Messersmith, Charles Zacharchuk, Kathleen Turnbull, Eric Leip, Poe-Hirr Hsyu, Nathalie Bardy-Bouxin, Shefali Agarwal, Richat Abbas, Gregory M. Springett, Elena G. Chiorean, Philip J. Gold, Mitesh J. Borad, Barbara J. Gitlitz, Mansoor N. Saleh, Smitha S. Krishnamurthi, Adil I. Daud
PDF file - 89K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f4587c6678ceb7f5636d4a877514e37
https://doi.org/10.1158/1078-0432.22444170
https://doi.org/10.1158/1078-0432.22444170
Publikováno v:
Drug Metabolism and Disposition. 45:390-398
Bosutinib is an orally available Src/Abl tyrosine kinase inhibitor indicated for the treatment of patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Bosutinib is predominantly metabolized by CYP3A4 as the primary clearance m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce4d6c9be3837937ac6e347b3626298f
https://doi.org/10.1124/dmd.116.074450
https://doi.org/10.1124/dmd.116.074450
Publikováno v:
Drug metabolism and pharmacokinetics. 34(2)
This article [1] has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the authors. According to the authors, their recent analyses ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d697035dec760c37adb21823dde64f56
https://pubmed.ncbi.nlm.nih.gov/24919837
https://pubmed.ncbi.nlm.nih.gov/24919837
Autor:
Richat Abbas, Poe-Hirr Hsyu
Publikováno v:
Clinical Pharmacokinetics. 55:1191-1204
Chronic myeloid leukemia (CML) is a clonal myeloproliferative stem cell disorder. Bosutinib is an oral, once-daily SRC/ABL tyrosine kinase inhibitor with very potent inhibitory activity. Bosutinib is effective against all phases of intolerant or resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d104004d64a4f62bf9e0202b40b64cab
https://doi.org/10.1007/s40262-016-0391-6
https://doi.org/10.1007/s40262-016-0391-6
Publikováno v:
Clinical pharmacology in drug development. 7(4)
This study evaluated the absolute bioavailability of bosutinib and assessed its safety and tolerability after single-dose oral and intravenous administration. In this phase 1 open-label, 2-sequence, 2-period crossover study, healthy, fed subjects age
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fffe2e794ebe3b8dc3d1f7c9de8624a
https://pubmed.ncbi.nlm.nih.gov/29058816
https://pubmed.ncbi.nlm.nih.gov/29058816
Publikováno v:
European journal of clinical pharmacology. 73(1)
Bosutinib, a dual Src and Abl tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia, demonstrated concentration-dependent inhibitory effects on P-glycoprotein (P-gp)-mediated digoxin efflux in vitro, suggesting that bosutinib may in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4028b4ec0c37313157143c4be3f5f2fa
https://pubmed.ncbi.nlm.nih.gov/27717999
https://pubmed.ncbi.nlm.nih.gov/27717999
Publikováno v:
European journal of clinical pharmacology. 73(1)
Bosutinib is an oral, dual Src and Abl tyrosine kinase inhibitor (TKI) approved for the treatment of Philadelphia chromosome—positive chronic myeloid leukemia resistant or intolerant to prior TKI therapy. Bosutinib is primarily metabolized by cytoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e66ca3f5b196fb51b802740937bee57
https://pubmed.ncbi.nlm.nih.gov/27718000
https://pubmed.ncbi.nlm.nih.gov/27718000
Autor:
Elena G. Chiorean, Barbara J. Gitlitz, Mitesh J. Borad, Nathalie Bardy-Bouxin, Wells A. Messersmith, Richat Abbas, Charles Zacharchuk, Kathleen Turnbull, Philip J. Gold, Adil Daud, Poe-Hirr Hsyu, Gregory M. Springett, Smitha S. Krishnamurthi, Shefali Agarwal, Mansoor N. Saleh, Eric Leip
Publikováno v:
Clinical Cancer Research. 18:1092-1100
Purpose: Bosutinib, a potent ATP-competitive, quinolinecarbonitrile Src/Abl kinase inhibitor, was tested in this first-in-human phase I trial in patients with advanced solid tumor malignancies. Patients and Methods: This trial was conducted in 2 part
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84b739b676b1699f8aa13ab1b35c6645
https://doi.org/10.1158/1078-0432.ccr-11-2378
https://doi.org/10.1158/1078-0432.ccr-11-2378
Publikováno v:
The Journal of Clinical Pharmacology. 46:1241-1249
HIV-seronegative subjects with hepatic impairment (6 mild, 6 moderate) and 12 matched healthy controls received nelfinavir 1250 mg every 12 hours with food for 2 weeks. Mild impairment did not significantly change nelfinavir or major metabolite (M8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33232e87507ba709091828b19f284688
https://doi.org/10.1177/0091270006292164
https://doi.org/10.1177/0091270006292164
Publikováno v:
Biopharmaceutics & Drug Disposition. 27:61-68
The effect of nelfinavir 1250 mg twice daily (b.i.d.) on the pharmacokinetics of methadone was determined in 14 HIV-negative methadone users. Design: The methadone dose (20–140 mg/day) was stabilized and fixed for at least 1 month before nelfinavir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43e5feb6dd4a4c8cdee7881d98bbb4df
https://doi.org/10.1002/bdd.482
https://doi.org/10.1002/bdd.482